Q2
EW — Q2 2026 Financial Report Analysis
Edwards grew Q2 2026 sales 13.6% to $1.74B (12.5% in constant currency) on TAVR and a 48% jump in mitral/tricuspid therapies, but GAAP EPS fell to $0.42 on a $188M California tax charge; adjusted EPS rose to $0.78 and sales guidance was raised.